WOCBP who are unwilling or unable to use an acceptable method of avoiding pregnancy for the entire study period
Patients who are otherwise felt unable to comply with the protocol, in the opinion of the investigator
Subject is unable or unwilling to participate a study related procedure
In the opinion of the Investigator patient is unable or unwilling to comply with the protocol.
Patients unable to comply with instructions for DIBH
Patients must not be pregnant or breast feeding, or unable or unwilling to use proper contraception during the study and up to 3 months following study completion (for treatment phase)
Patients unwilling to or unable to comply with the protocol
Patient unable or unwilling to comply with the protocol requirements
Patients who are unwilling to comply with protocol
Patients unwilling to or unable to comply with the protocol
Unable/unwilling to undergo bone marrow sampling
Unwilling or unable to comply with the requirements of the study protocol
Patients unable or unwilling to abide by the study protocol or cooperate fully with the investigator
Unwilling or unable to provide written informed consent, comply with study requirements, or be available for follow-up assessments
Patients unable to comply with the protocol
Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
Subjects must be unwilling or unable to tolerate other non-study systemic chemotherapy.
DONOR: Donors who are unwilling or unable to sign informed consent (assent when appropriate)
Patient is unwilling or unable to comply with study procedures, or is planning to take vacation for 7 or more consecutive days during the treatment phase of the study without prior consent from the medical monitor
Unwilling or unable to follow protocol requirements
For female patients of childbearing potential (defined as having had a menstrual period within the past 12 months): a positive serum pregnancy test (?-human chorionic gonadotropin [? HCG]) within 7 days prior to enrollment; or unwilling or unable to undergo hormonal suppression to avoid menstruation during treatment; or if breastfeeding, unwilling or unable to stop breastfeeding while on study treatment.
Patients unable or unwilling to adhere to the study assessment schedule.
Patients unwilling or unable to comply with the study protocol.
Unwilling or unable to participate in all required study evaluations and procedures
Unwilling or unable to participate in all required study evaluations and procedures
Unwilling or unable to follow protocol requirements
The subject or guardian is unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up and research tests.
Unwilling or unable to participate in all required study evaluations and procedures
Unwilling or unable to follow protocol requirements
Patients unwilling to or unable to comply with the protocol
Patients unwilling or unable to comply with the protocol
Unwilling or unable to follow protocol requirements
Patients unwilling or unable to comply with the protocol
Unwilling or unable to follow protocol requirements
Patients assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
Unwilling or unable to follow protocol requirements.
Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up, and research tests.
Patients unwilling or unable to comply with the protocol
Subject is unable or unwilling to abide by the study protocol or cooperate fully with the Investigator or designee.
Unable or unwilling to sign the consent form
Unwilling or unable to follow protocol requirements
Unable or unwilling to sign the consent form
Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, long-term follow-up, and research tests.
The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Unwilling or unable to provide informed consent or comply with the requirements of this protocol, including the presence of any condition (physical, mental or social) that is likely to affect the subject's return for scheduled visits and follow-up.
Unwilling or unable to follow protocol requirements
Patients who are unwilling or unable to comply with all study requirements
Patients unwilling or unable to comply with the protocol.
Patients who are unwilling or unable to undergo an apheresis for production of their vaccine
Patients unable or unwilling to provide informed consent.
Patients unable or unwilling to return to the transplant center for their assigned treatments.
Unwilling or unable to follow protocol requirements
Unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.
Unwilling or unable to follow protocol requirements
Patients unable or unwilling to abide by the study protocol or cooperate fully with the investigator
Patients unable or unwilling to undergo a biopsy for research during the screening period, 2-3 weeks into the course of therapy and at the time of progression
Unable or unwilling to discontinue concomitant use of drugs that are known to prolong the QT interval.
Unwilling or unable to follow protocol requirements
Unable to read or understand, and/or unwilling to sign a written consent form which must be obtained prior to treatment.
Patients unable or unwilling to give written, informed consent.
Patients unwilling to comply with study protocol
Unable or unwilling to sign the consent form
Patient is unwilling or unable to comply with study procedures
Unwilling or unable to participate in all required study evaluations and procedures
Unable or unwilling to follow post-therapy radiation protection procedures
Patients are not eligible if they are unwilling or unable to comply with the protocol
Unable to comply with the requirements of the protocol, or unable to provide adequate informed consent in the opinion of the principal investigator
Is unwilling or unable to comply with study requirements
Unwilling or unable to participate in all required study evaluations and procedures
WOCBP who are unwilling or unable to use an acceptable method to minimize the risk of pregnancy for the entire study period and for at least 23 weeks after the last dose of investigational product
Patient is unwilling or unable to follow the study schedule for any reason
Unwilling or unable to follow protocol requirements
Patients unwilling or unable to comply with the protocol
Unwilling or unable to follow protocol requirements
Unwilling or unable to participate in all required study evaluations and procedures
Patients unwilling to or unable to comply with the protocol
Unable or unwilling to communicate or cooperate with the Investigator or follow the protocol for any reason
Patients who, in the investigator's judgment, are unwilling or unable to consent to and return for recommended post-treatment scans as outlined in this study
Unwilling or unable to participate in all required study evaluations and procedures
DONOR: Unwilling or unable to provide informed consent
Unable or unwilling to sign the consent form
Unwilling or unable to follow protocol requirements
Subjects who are unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee are excluded
Patients unwilling or unable to comply with the protocol
Patient is unable or unwilling to sign consent
Patients unwilling to or unable to comply with the protocol
Unable or unwilling to communicate or cooperate with the Investigator or follow the protocol for any reason
Unable or unwilling to swallow the complete daily dose of ARQ 751
Unwilling or unable to participate in all required study evaluations and procedures
Unable or unwilling to tolerate an intracranial MRI
Subject is unable or unwilling to discontinue use of prohibited medications
Subject is unable or unwilling to participate in a study related procedure
Patient is unwilling or unable to follow the study schedule for any reason
Patients who are not available for follow-up assessments or unable to comply with study requirements
Unwilling or unable to stop oral supplemental vitamin D
Unable to comply with protocol
The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Unwilling or unable to provide informed consent
Patients unwilling or unable to comply with the protocol
Patients unwilling or unable to comply with the protocol
Patients unwilling or unable to comply with the protocol
The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Unwilling or unable to follow protocol requirements
Unable or unwilling to swallow ARQ 092 or anastrozole or comply with chemotherapy regimen
Unable or unwilling to sign the consent form
Patients unwilling or unable to comply with the protocol
Unwilling or unable to comply with the safety monitoring requirements of this protocol
Patients unwilling or unable to comply with the protocol
Patients unwilling to or unable to comply with the protocol
Unwilling or unable to follow protocol requirements
Unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Patient is unable or unwilling to abide by the study protocol or cooperate fully with the investigator
Unwilling or unable to follow protocol requirements
Unable or unwilling to sign the consent form
Unwilling or unable to follow protocol requirements
Patients who are unwilling or unable to comply with study and/or follow-up procedures
Patients unwilling or unable to comply with the protocol
The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Patient is unable or unwilling to abide by the study protocol or cooperate fully with the investigator
Patients unable or unwilling to swallow pills
Patients unwilling or unable to comply with the protocol
Unable to render informed consent and to follow protocol requirements
The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Patients is unwilling or unable to comply with study procedures
Unwilling or unable to follow protocol requirements
Patient is unable or unwilling to provide written informed consent or comply with follow-up schedule
Unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Patients unwilling or unable to comply with the protocol
Unwilling or unable to follow protocol requirements
Unwilling or unable to follow protocol requirements
Unwilling or unable to follow protocol requirements
Unwilling or unable to, comply with the protocol
Patients unwilling or unable to sign informed consent document
Patients unwilling or unable to sign informed consent document
Patients unwilling to or unable to comply with the protocol
Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up and research tests
Patients unwilling or unable to comply with the outlined protocol
Patient unwilling to or unable to comply with the protocol
Unable or unwilling to give voluntary informed consent/assent
Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up, and research tests
Unable or unwilling to sign the consent form
Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
Unwilling or unable to follow protocol requirements
Unable to provide informed consent or, in the opinion of the Principal Investigator, comply with the protocol.
Unwilling or unable to complete study diary
Are unable or unwilling to follow protocol instructions and requirements
Is, in the judgment of the investigator, unable or unwilling to comply with the requirements of the study.
Unable or unwilling to undergo a 7 day washout period if currently being treated with deferiprone or deferoxamine or deferasirox;
Patient is unable or unwilling to abide by the study protocol or cooperate fully with the investigator
Patients who are unwilling or unable to use 2 highly effective methods of contraception as outlined in this protocol
Patients unwilling or unable to comply with the protocol, or provide informed consent.
Unable or unwilling to adhere to the study-specified procedures and restrictions
Patients who are unable to provide informed consent, are incarcerated, or are unable to follow protocol requirements.
Unwilling or unable to follow protocol requirements
Patients unwilling to or unable to comply with the protocol
Adults unable to consent
Patients unwilling or unable to comply with the protocol, or provide informed consent
Patients unwilling or unable to comply with the protocol, or provide informed consent
The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Unwilling or unable to follow protocol requirements
Patients with untreated AML who are either unwilling or unable to undergo high-dose induction/consolidation intensive chemotherapy
The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Unwilling or unable to participate in all required study evaluations and procedures
Patients who are unable or unwilling to abide by the study protocol or to cooperate fully with the investigator or designee
WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of investigational product
Patients unwilling or unable to comply with the study protocol
Unable and unwilling to provide informed consent
Patients unwilling to or unable to comply with the protocol
Unwilling or unable to follow protocol requirements
Unwilling or unable to follow protocol requirements
Patient is unable or unwilling to abide by the study protocol or cooperate fully with the investigator
Unable to comply with the requirements of the protocol, or unable to provide adequate informed consent in the opinion of the principal investigator
Unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Unable or unwilling to undergo protocol required thromboembolism prophylaxis(for Cohort C, this will be only for the subjects who have a history of VTE)
Is unable or unwilling to take folic acid or vitamin B12 supplementation.
Subjects unwilling to or unable to comply with the protocol
Patients who are unable to swallow oral medication or are unwilling to comply with the administration requirements are not eligible
Unwilling or unable to follow protocol requirements
Unwilling or unable to follow protocol requirements
Unwilling or unable to participate in all required study evaluations and procedures
Subject is unwilling or unable to comply with study procedures
Patients unwilling or unable to comply with this study protocol
Patients unwilling or unable to comply with the protocol
Unwilling or unable to follow protocol requirements or to give informed consent
Unwilling or unable to participate in all required study evaluations and procedures
Unwilling or unable to participate in all required study evaluations and procedures
Patients unwilling or unable to comply with the protocol
Unwilling or unable to comply with the protocol or cooperate fully with the investigator and site personnel
Subject is unwilling or unable to comply with study procedures
Patients unable to comply with the protocol as judged by the investigator.
Patients unwilling or unable to comply with the protocol
Patients unwilling to or unable to comply with the protocol
WOCBP who are unwilling or unable to use an acceptable method to minimize the risk of pregnancy for the entire study period and for at least 12 weeks after the last dose of investigational product
Patient unable to consent or comply with study guidelines
Patients unwilling or unable to comply with the protocol
The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Patients unwilling or unable to sign informed consent document.
Unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Is unable or unwilling to participate in a study related procedure
Patients unwilling to or unable to comply with the protocol.
Unable or unwilling to sign the informed consent document
Unwilling to or unable to comply with the protocol
Unwilling or unable to comply with the protocol
Subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Unwilling or unable to comply with the protocol
Patients unwilling or unable to comply with the protocol
Patients unable or unwilling to give written, informed consent
Unwilling or unable to follow protocol requirements
Unwilling or unable to comply with the protocol
Patients unwilling or unable to comply with the protocol
Patient is unwilling or unable to follow the study schedule for any reason
Patient is unable or unwilling to abide by the study protocol or cooperate fully with the investigator
Male subjects unable or unwilling to use adequate contraception methods from study start to 30 days after the last dose of protocol therapy
Unable or unwilling to undergo antithrombotic prophylaxis
Unwilling or unable to undergo a MRI or CT Scan per study protocol requirements
Unwilling or unable to follow protocol requirements
Is unable to comply with study requirements
Unable to consent for study
Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
Unable to give informed consent or comply with clinical trial requirements
Patients unwilling or unable to provide informed consent for the study
Is unable to follow study procedures
Unwilling or unable to participate in all required study evaluations and procedures
Unwilling or unable to follow protocol requirements
Unwilling or unable to participate in all required study evaluations and procedures
Unwilling or unable to follow protocol requirements
Unwilling or unable to follow protocol requirements
Unwilling or unable to follow protocol requirements
Patient is unable or unwilling to abide by the study protocol or cooperate fully with the investigator
Patients unwilling to or unable to comply with the protocol
Participants unwilling or unable to comply with the protocol
Unable or unwilling to swallow the complete daily dose of ARQ 087
Patients unwilling or unable to sign informed consent document
Patients who are not available for follow-up assessments or unable to comply with study requirements
Patient unable to comply with the protocol, in the opinion of the investigator.
Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy
Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up, and research tests
Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy
The participant is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy
Patients unwilling to or unable to comply with the protocol
Unwilling or unable to follow protocol requirements
WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study and for up to 8 weeks after the last dose of investigational product
Patients unwilling or unable to comply with the protocol
Unable or unwilling to sign the consent form
The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Patient is unable or unwilling to abide by the study protocol or cooperate fully with the investigator
Patients unwilling to or unable to comply with the protocol
Patients unwilling or unable to sign informed consent document
Patient is unable or unwilling to discontinue predefined prohibited medications listed in the protocol for 4 weeks of a drug (whichever is longer) prior to Visit 1 and for the duration of the study
Patients unwilling or unable to comply with protocol therapy, tests, and visits, or with a history of noncompliance with medical regimens
EXPANSION COHORT ONLY: Patient is unable or unwilling to discontinue predefined prohibited medications listed in the protocol for 4 weeks of a drug (whichever is longer) prior to visit 1 and for the duration of the study
EXPANSION COHORT ONLY: Patients unwilling or unable to comply with protocol therapy, tests, and visits, or with a history of noncompliance with medical regimens
Unwilling or unable to participate in all required study evaluations and procedures
Patients unwilling to comply with the protocol
Unable or unwilling to provide informed consent.
Unable or unwilling to adhere to the study-specified procedures and restrictions
Subjects unwilling to or unable to comply with the protocol procedures as assessed by the Investigator
Subject unwilling or unable to comply with study requirements
Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up and research tests
Patients unwilling or unable to comply with the protocol
Is unwilling or unable to abide by the requirements of the study.
Unwilling or unable to participate in all required study evaluations and procedures.
Patient is unable or unwilling to abide by the study protocol or cooperate fully with the investigator
Patients unable to comply with the protocol
Subject is unwilling or unable to comply with study procedures.
WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of chemotherapy
Unwilling or unable to follow protocol requirements
Unwilling or unable to follow protocol requirements
Unwilling or unable to follow protocol requirements
Unable or unwilling to take folic acid or vitamin B12
Unable or unwilling to complete the follow-up evaluations required for the study
Unwilling or unable to follow protocol requirements and the light exposure precautions
Unwilling or unable to follow protocol requirements
Patient is unwilling or unable to comply with study procedures
Unable to comply with the study follow-up schedule
The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Patient is unwilling or unable to comply with study procedures
Patient unable or unwilling to comply with the protocol requirements
Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy
The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Unwilling or unable to follow protocol requirements
Patients unwilling or unable for any reason (personal, medical, or psychiatric) to comply with the protocol
Patients unwilling or unable to comply with the study protocol
Unwilling or unable to undergo a MRI per requirements in the study protocol
The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Patient unable or unwilling to comply with the protocol.
Subjects unable or unwilling to comply with the study visit schedule and requirements of the study
Subjects who are unable or unwilling to comply with all study requirements for clinical visits, examinations, tests, and procedures.
Woman of childbearing potential unwilling or unable to use adequate contraception
Unwilling or unable to take oral medication
Unwilling or unable to participate in all required study evaluations and procedures
Patient is unwilling or unable to comply with the follow-up schedule
Patients unwilling or unable to comply with the research protocol
In Part 2, unable or unwilling to consent to provision of tumor tissue for GR assay
Is unwilling or unable to comply with study procedures, or is planning to take a vacation for 7 or more consecutive days during the treatment phase of the study
Unable or unwilling to comply with all protocol requirements.
Unwilling to, or unable to, comply with the protocol
Unwilling or unable to follow protocol requirements
Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
Patients unwilling to use contraceptives while on study
Unable or unwilling to abide by the study protocol or cooperate fully with the investigator
Patients unwilling or unable to comply with the protocol
The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Patient is unable to comply with the requirements of the study.
Patients unwilling to or unable to comply with the protocol
WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 12 weeks after the last dose of investigational product
Unwilling or unable to have a central venous catheter
Subjects unable or unwilling to undergo antithrombotic prophylactic treatment
Patient is unable or unwilling to abide by the study protocol or cooperate fully with the investigator
Patients unable to comply with the protocol
Patients who are unwilling or unable to comply with the protocol are not eligible
The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Patients unwilling to or unable to comply with the protocol
Patients who are unable or unwilling to undergo antithrombotic therapy.
Subject is unwilling or unable to follow the procedures outlined in the protocol.
Unwilling or unable to follow protocol requirements
Patients unwilling or unable to comply with the protocol
Patients who are unwilling or unable to comply with the protocol
Unwilling or unable to follow protocol requirements
Unwilling or unable to follow protocol requirements
Unwilling or unable to follow protocol requirements
Unwilling or unable to comply with the protocol
Unwilling or unable to participate in the study
Unable to comply with the protocol for any reason
Unwilling or unable to follow protocol requirements
Unwilling or unable to follow protocol requirements
Unwilling or unable to participate in the study
Unwilling or unable to participate in the study
Unwilling or unable to participate in the study
Unwilling to give consent
Unable or unwilling to discontinue consuming soy-based food or supplements while participating in this study
Anyone who, in the investigator’s discretion, would be unwilling or unable to comply with study procedures
Unable and unwilling to provide informed consent
Unwilling to give consent
Unwilling to undergo routine follow-up
Are unable or unwilling to discontinue anxiolytics within 4 hours of education sessions
Subjects who are unable or unwilling to discontinue use of prohibited medications
Unable to cooperate with research procedures
Unwilling to receive acupuncture or unable to travel for treatments
Unable or unwilling to sign consent
Unwilling or unable to participate in the study
Unwilling or unable to follow protocol requirements
Unable or unwilling to give written informed consent
Patients unable to apply Estring
Unable/unwilling to sign consent
Unwilling or unable to follow protocol requirements
Unwilling or unable to provide informed consent or comply with the requirements of this protocol, including the presence of any condition (physical, mental or social) that is likely to affect the subject's return for scheduled visits and follow-up.
Unwilling or unable to comply with the protocol
Unable or unwilling to abide by the study protocol or cooperate fully with the Investigator or designee.
Unwilling or unable to participate in all required study evaluations and procedures
Unwilling or unable to participate in all required study evaluations and procedures
The patient is unwell or unable to participate in all required study evaluations and procedures
Unwilling or unable to provide informed consent
Unable to comply with protocol and/or not available for follow-up assessments
Unwilling or unable to follow protocol requirements
Be unable or unwilling to discontinue anxiolytic medication within 4 hours of intervention sessions
Is unwilling or unable to agree to swish and spit the study oral rinse three times per day during the study period
Unwilling or unable to sign and date the informed consent
Unwilling or unable to comply with the follow-up schedule
Patients unwilling or unable to comply with the protocol
Unable to comply with the protocol for any reason
Unable or unwilling to comply with study procedures
Patients unable to consent for the procedure
Patients unwilling or unable to provide consent
Unwilling or unable to provide consent
Adults unable to consent
Patient unable to comply with the treatment protocol including appropriate supportive care, follow-up and research tests
EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Unwilling or unable to participate in all required study evaluations and procedures
Unwilling or unable to follow protocol requirements
Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up and research tests
Patients unwilling to comply with study requirements
Unable to understand instruction and to follow protocol requirements
Unwilling or unable to follow protocol requirements
Unable or unwilling to provide informed consent
Unable or unwilling to adhere to study-specified procedures
Subjects unable or unwilling to comply with the study visit schedule and requirements of the study
Patients unwilling or unable to comply with the study protocol
Unable or unwilling to adhere to a carbohydrate-restricted dietary intervention
If, in the opinion of the Investigator, the patient is deemed unwilling or unable to comply with the requirements of the Study
Patient unwilling or unable to provide informed consent.
Unwilling or unable to follow the protocol requirements.
Subjects unwilling or unable to given written informed consent
Subject is unwilling to comply with the requirements of the protocol
Patients unwilling or unable to sign informed consent
Unwilling or unable to follow protocol requirements
Subject is unable or unwilling to follow study requirements, including signed consent or assent
Participants unable or unwilling to give written, informed consent or to undergo MRI imaging
Unable or unwilling to give informed consent
Patients unable or unwilling to provide informed consent
Subjects that are unable or unwilling to give informed consent
Unwilling or unable to follow protocol requirements
Unable or unwilling to give informed consent
Patients who are unable to give consent
Unable or unwilling to discontinue concomitant drugs that are known to prolong the QT interval
Unable to understand, or unwilling to complete the informed consent process
Unable or unwilling to follow protocol requirements
Patient under guardianship and/or unable or unwilling to cooperate with the requirements of this trial
Patient is unable (or unwilling) to provide informed or surrogate (as appropriate) consent
Subjects who are unable or unwilling to give informed consent
Unable/unwilling to follow protocol requirements
Unwilling or unable to follow protocol requirements
Unwilling or unable to follow protocol requirements
Are unwilling or unable to participate in, or do not have tissue adequate for participation in the biomarker analyses in the study.
Unwilling or unable to participate in the study
Unwilling or unable to receive home health care
Are unable to consent
Patients who are unable or unwilling to give informed consent
Men whose partner is unwilling or unable to avoid pregnancy
